Copied from Croda's web site, it gives a quick insight into the niche markets in which this company specialises ...... They also own Uniquema, which is how the latter fits in ......

Croda isnt a household name but household names have made us successful. Within our core speciality chemicals business we focus on personal care, health care, home care and plastics additive markets.

Uniqema (cynic adds - acquisition completed 1/9/06) provides base oleochemicals such as fatty acids, polymerised fatty acids, glycerine and soap to a global market. With years of experience and technical advancements, Uniqema is a global market leader.


Now you have the outline, here are the charts to follow ..... Croda has generally been a steady performer, and none the worse for it ...... the chart today, following the announcement of a sale of a part of the biz, sp has moved upwards with indications that it could be about to break upwards .... and i have backed my mouth with my money

intrinsically a very good company, though quite illiquid to trade.
results were less than inspiring, and coupled to the announcement to shut one of their plants and a weak chart pattern, this is NOT the time to buy

Good run lately on back of generally improved market and hopes for return to profits in industrial chemicals division (made loss at half year and should be scope for decent recovery) - home/personal care continues to grow. Third quarter update due in a couple of weeks. I have recently top sliced to bank some profit, but this remains core holding in my ISA. Always DYOR.

http://www.proactiveinvestors.co.uk/companies/news/9480/chemicals-specialist-croda-international-continues-to-deliver-solid-returns-9480.html

Having a great run, on my short list (probably a bit more upside to come) but due a pull back my instinct being prior to third quarter results. Good trading play.

Well worth having a trading long in this stock looking at the chart.



855p target SP.

this is another top notch company, though trading can be pretty thin ..... sp just challenging new all-time high ...... buy now? ..... arguably better to wait for the break

Very impressive backing from the brokers....


Croda International PLC

FORECASTS
2009 2010

Date Rec Pre-tax () EPS (p) DPS (p) Pre-tax () EPS (p) DPS (p)

W H Ireland Ltd
27-11-09 MPER 100.00 48.10 20.50 115.00 55.30 22.00

Charles Stanley
20-11-09 BUY 100.00 51.50 20.50 113.00 57.00 22.75

Collins Stewart
02-11-09 BUY 50.00 60.40

ABN AMRO
02-10-09 HOLD 91.92 44.75 20.56 105.47 51.35 23.59

Speirs & Jeffrey Ltd
29-09-09 BUY 94.60 44.90 20.70 109.60 53.80 21.80

Eden Group
03-07-09 BUY

2009 2010

Pre-tax () EPS (p) DPS (p) Pre-tax () EPS (p) DPS (p)

Consensus 97.92 49.09 20.52 110.68 55.03 22.06
1 Month Change 3.33 -0.04 0.00 0.08 0.05 0.01
3 Month Change -2.02 1.01 0.00 -3.63 0.07 -0.20


GROWTH
2008 (A) 2009 (E) 2010 (E)

Norm. EPS 69.45% -7.28% 12.10%
DPS 16.44% 20.71% 7.50%

INVESTMENT RATIOS
2008 (A) 2009 (E) 2010 (E)

EBITDA 154.20m 147.26m 168.48m

EBIT 120.20m m m

Dividend Yield 2.20% 2.66% 2.86%

Dividend Cover 3.11x 2.39x 2.50x

PER 14.57x 15.72x 14.02x

PEG 0.21f -2.16f 1.16f

Net Asset Value PS 43.17p 197.47p 206.25p


Way undervalued on a forward P/E of just 14 to 2010

Splendid results today and optimistic opinion about 2010. A high quality business and it has been an excellent PEP/ISA investment to date.

what a clever chap i am! ...... i start the thread saying what a good company this is, and then completely forget about it!!

Excellent results yesterday. Quality business.

bought into this on Guy Fawkes Night, and what a little sparkler it has developed into

Stunning first quarter figures this morning. Superb business.

Continues to outperform, but must admit to having banked a bit more profit. Still a core holding in ISA.

i am such a wuss! .... i start the thread extolling the virtues of the stock, but haven't held for ages! .... perhaps i should marry some money to the gob even now

Croda is a specialist chemicals company with an impressive track record. For the last three years the company has delivered, on average, annual eps growth of 33% and dividend growth of 43% per annum.

One of Croda's specialities is providing raw materials for the cosmetics industry. In the company's most recent trading statement, Croda reported a 13.7% increase in profits from this division. Cosmetics companies seem to have successfully convinced men that they also need the products only women ever used to buy. This presents real revenue growth opportunities for Croda.

The market demands investors stump up for shares in this huge success story. The company today trades on 18.4 times 2011's earnings and 16.9 times the 2012 consensus forecast.

Croda demonstrates how the market will reward success -- especially if it can be convinced the success will continue. Croda lacks exposure to the financial sector and only has indirect consumer risk. As such, the shares have been somewhat unaffected by the current panic.

Perhaps investors should not be surprised how well Croda shares have done. Unfortunately, at today's price it looks like Croda's biggest gains may have already been made. If you are looking for a cheaper alternative, Treatt might be worth examining. Treatt is a similar business to Croda but trades on a lower P/E rating and pays a higher dividend

Stretching a point to compare CRDA (sales £1BN+) with TET (sales £75M) but I have held both in ISA for a number of years and hold each of them in high regard. Always dyor.

Stock added to Bullish Trending Charts over on Chart Attack thread.

Speciality chemicals group Croda International was another high riser after JP Morgan Cazenove upgraded the stock to 'overweight', lifting its target price from 2,220p to 2,600p.

Chemicals company Croda International was in demand as traders remained ambivalent about which direction stockmarkets are heading.

Croda, which makes speciality chemicals for beauty and healthcare products, perked up 58p to £21.83 on speculation its second-quarter figures, due on July 24th, will beat market expectations.

Martin Evans, an analyst at JP Morgan Cazenove, appeared to trigger the speculation after he said in a note that second-quarter results are likely to be "robust".

"Some year-on-year currency pressure from the adverse £/€ rate is likely ... but equally input costs we suspect have begun to trend lower which may provide a cushion in the second quarter," said Mr Evans.

Mr Evans who upgraded the Croda to "overweight" from "neutral" concluded: "The combination of newer products and relatively robust pricing initiatives should allow the high margins of around 30pc to be maintained - or even go slightly higher as costs remain under control and price rises benefit the overall return."

One for the Sipp. yup